





IFW

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Signature and Deposit: September 20, 2004

   
Zeb

Zhibin Ren 47,897

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Fritz Sieber, et al.

Date: September 20, 2004

Serial No.: 10/701,870

Group Art Unit: 1645

Filed: 11/05/2003

Examiner: N/A

Title: METHOD OF MAKING, AND THE USE OF  
CYTOTOXIC AGENTS CONTAINING  
ELEMENTAL SELENIUM

File: 650053.91649

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is a completed Information Disclosure Statement by Applicant listing documents that the applicants in the above-identified application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this application.

No fee is believed due in connection with this submission. However, if a fee is due, please charge the fee to Deposit Account No. 17-0055.

Respectfully submitted,

  
Zeb  
Zeb  
Zhibin Ren  
Reg. No. 47,897  
Attorney for Applicants  
QUARLES & BRADY LLP  
411 East Wisconsin Ave.  
Milwaukee, WI 53202  
TEL 414-277-5633  
FAX 414-978-8663



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet 1 of 3

**Complete if Known**

Application Number	10/701,870
Filing Date	11/05/2003
First Named Inventor	Fritz Sieber
Art Unit	1645
Examiner Name	N/A
Attorney Docket Number	650053.91649

## U. S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>2</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>3</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.4. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO **THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>
				<b>Application Number</b> 10/701,870
				<b>Filing Date</b> 11/05/2003
				<b>First Named Inventor</b> Fritz Sieber
				<b>Art Unit</b> 1645
				<b>Examiner Name</b> N/A
Sheet	2	of	3	Attorney Docket Number 650053.91649

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	2	Günther WHH, Searle R. and Sieber F; Structure-Activity Relationships in the Antiviral and Antileukemic Photoproperties of Merocyanine Dyes; Seminars in Hematology, Vol. 29, No. 2, pp. 88-94, 1992.		
	3	Günther WHH, Searle R and Sieber F; Photosensitizing Merocyanine Dyes Based on Selenobarbituric Acid; Phosphorus, Sulfur, and Silicon, Vol. 67: pp. 417-424, 1992.		
	4	Krieg M, Bilitz JM, Traul DL and Sieber F; Photosensitizing Oxonol Dyes with Antineoplastic Activity, Cancer Research, Therapy and Control, Vol. 4, pp. 163-172, 1995.		
	5	Burger AM, Hartung G, Stehle G, Sinn H, Fiebig HH: Pre-Clinical Evaluation of a Methotrexate-Albumin Conjugate (MTX-HSA) in Human Tumor Xenografts In Vivo; Int. J. Cancer: 92, 718-724, 2001.		
	6	Wunder A, Müller-Ladner U, Stelzer EHK, Funk J., Neumann E, Stehle G, Pap T, Sinn H, Gay S, Fiehn C; Albumin-Based Drug Delivery as Novel Therapeutic Approach for Rheumatoid Arthritis; The Journal of Immunology, 170, 4793-4801, 2003.		
	7	Yan L, Yee JA, Boylan LM, Spallholz JE; Effect of Selenium Compounds and Thiols on Human Mammary Tumor Cells, Biological Trace Element Research, Vol 30, pp. 145-162, 1991.		
	8	Zhang J-S, Gao X-Y, Zhang L-D, Bao Y-P; Biological effects of a nano red elemental selenium, BioFactors 16, 27-38, 2001.		
	9	Huang B, Zhang J, Hou J, Chen C; Free Radical Scavenging Efficiency of Nano-Se In Vitro; Free Radical Biology & Medicine, Vol. 35, No. 7, pp. 805-813, 2003.		
	10	Sieber F, Daziano J-P, Anderson GS, Miyagi K, Sampson RW, Tsujino I, Günther WHH, Krieg M, Bousbaa J and Försterling FH; Colloidal Selenium Generated by Photobleaching of Selenomerocyanine Dyes Combines with Serum Macromolecules to Form Conjugates that are Preferentially Cytotoxic to Leukemia and Selected Solid Tumor Cells; Blood 100, 224b, 2002.		
	11	Miyagi K, Sampson RW, Tsujino I, Gunther WHH, Krieg M and Sieber F; Proteinated subnanoparticles of elemental selenium potentiate the anti-tumor effect of ionizing radiation and selected chemotherapeutic agents; Proceedings of the American Association Cancer Research, Vol. 44, 385, 2003.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Please type a plus sign (+) inside this box →  +

PTO/SB/08B (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	10/701/870
		Filing Date	11/05/2003
		First Named Inventor	Fritz Sieber
		Group Art Unit	1645
		Examiner Name	N/A
Sheet	3	of	3
		Attorney Docket Number	650053.91649

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.